Abstract: Devices, methods, and systems are described for administration to at least one biological tissue of at least one device including at least one altered microorganism. In an embodiment, the altered microorganism includes at least one nucleic acid construct encoding at least one therapeutic agent.

Abstract: A system and method for providing media and/or advertising content determines content and/or parameters responsive to physical and/or physiological information about a viewer detected by a micro-impulse radar (MIR).

Abstract: A micro-impulse radar (MIR) may be configured to provide information about at least one person in a region. A media output device may be driven responsive to the information to output media content to the at least one person.

Abstract: Devices, methods, and systems are described for administration to at least one biological tissue of at least one device including at least one altered microorganism. In an embodiment, the altered microorganism includes at least one nucleic acid construct encoding at least one therapeutic agent.

Abstract: Devices, methods, and systems are described for administration to at least one biological tissue of at least one device including at least one altered microorganism. In an embodiment, the altered microorganism includes at least one nucleic acid construct encoding at least one therapeutic agent.

Abstract: Systems and methods described herein include those for the continual modification of intestinal microbes. Described herein are systems including sampling devices, analysis devices, computational devices and user interface devices as well as methods for the use of such devices in combination.

Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure targeted to a lipid bilayer membrane. The targeted tubular nanostructure can have a surface region configured to pass through a lipid bilayer membrane of a cell, a hydrophobic surface region flanked by two hydrophilic surface regions configured to form a pore in a lipid bilayer membrane of a cellular organelle, and at least one ligand configured to bind one or more cognates on the lipid bilayer membrane of the cellular organelle. The target cell can be, for example, a tumor cell, an infected cell, or a diseased cell in a subject. The tubular nanostructure can form a pore in the lipid bilayer membrane of the cellular organelle, e.g., mitochondria, which can permit transit or translocation of at least one compound across the membrane and cause cell death of the target cell.

Abstract: Computational methods and systems are described which accept input, identify one or more CYP450-family enzymes, identify one or more modulators of the CYP450-family enzymes, and communicate treatments to at least one system user, wherein the treatments include one or more of the identified at least one modulator.

Abstract: Methods and systems such as those described herein include accepting input, identifying CYP450-family enzymes, identifying at least one modulator of an enzyme, and communicating one or more treatments to a system user.

Abstract: Provided embodiments include a final dosage form, an article of manufacture, and a method. A method of fulfilling a request specifying a dose of a medicament for an individual animal includes choosing pursuant to the request an instance of a final dosage form that includes the medicament. The method also includes selecting a stimulus effective to change a medicament-release state of a release element of the final dosage form. The method further includes initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus. The method further includes the release element configured in a first medicament-release state and changeable to a second medicament-release state upon an ex vivo exposure to a stimulus.

Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure targeted to a lipid bilayer membrane. The targeted tubular nanostructure can have a surface region configured to pass through a lipid bilayer membrane of a cell, a hydrophobic surface region flanked by two hydrophilic surface regions configured to form a pore in a lipid bilayer membrane of a cellular organelle, and at least one ligand configured to bind one or more cognates on the lipid bilayer membrane of the cellular organelle. The target cell can be, for example, a tumor cell, an infected cell, or a diseased cell in a subject. The tubular nanostructure can form a pore in the lipid bilayer membrane of the cellular organelle, e.g., mitochondria, which can permit transit or translocation of at least one compound across the membrane and cause cell death of the target cell.

Abstract: Described embodiments include a final dosage form for administering a medicament to an animal, an article of manufacture, and method. A described final dosage form includes a medicament. The final dosage form also includes a release-control substance carrying the medicament in a first medicament-release state wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal. The release-control substance is modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal. The release-control substance is modifiable ex vivo by an exposure to second stimulus to carry the medicament in a third medicament-release state wherein the medicament has a third bioavailability to the animal if the final dosage form is administered to the animal.

Abstract: Provided embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for delivering a medicament to an animal is provided. The final dosage form includes an outer layer. The final dosage form also includes a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to a stimulus. The final dosage form further includes a chamber at least substantially within the outer layer and configured to carry the medicament. The final dosage form includes the medicament. The final dosage form may include an indicator element configured to indicate an exposure of the release element to the stimulus.

Abstract: Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a dosage portion having a chamber carrying a medicament. The dosage portion also has a release element in a first medicament-release state wherein the medicament has a first bioavailability to the animal. The release element is modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal. The final dosage form includes another dosage portion having another chamber carrying another medicament. The another dosage portion also has another release element in another first medicament-release state wherein the another medicament has another first bioavailability to the animal. The another release element is modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal.

Abstract: Provided embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for administering a medicament to an animal is provided. The final dosage form includes the medicament, and a particle or polymeric material. The particle or polymeric material carries the medicament and is configured in a medicament-retention state. In medicament-retention state, the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal. The particle or polymeric material is modifiable ex vivo by an exposure to a stimulus to a medicament-release state. In the medicament-release state, the medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal.

Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure or a composite tubular nanostructure targeted to a lipid bilayer membrane. The tubular nanostructure includes a hydrophobic surface region flanked by two hydrophilic surface regions. The tubular nanostructure is configured to interact with a lipid bilayer membrane and form a pore in the lipid bilayer membrane. The tubular nanostructure may be targeted by including at least one ligand configured to bind to one or more cognates on the lipid bilayer membrane of a target cell.

Abstract: Described embodiments include a system. A described system includes a computer-readable storage medium configured to indicate a stimulus to modify ex vivo a bioavailability of a medicament carried by a final dosage form based upon a selected medicament bioavailability of the final dosage form. The system also includes a holder configured to establish ex vivo of the animal a location of the final dosage form to receive the indicated stimulus from a stimulus source. The system further includes the stimulus source operable to provide the indicated stimulus. The system also includes a stimulation controller operable to regulate an ex vivo exposure of the final dosage form to the indicated stimulus.

Abstract: Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a medicament, and a substance associated with the medicament in a first release-control state. In the first release-control state, the medicament has a first bioavailability to the animal. The substance is modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal. The final dosage form also includes another medicament, and another substance associated with the another medicament in another first release-control state. In the another first release-control state, the another medicament has another first bioavailability to the animal. The another substance is modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability.

Abstract: Described embodiments include a final dosage form for administering a medicament to an animal, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament and a release element in a first medicament-release state. The medicament has a first bioavailability to the animal. The release element is modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal. The final dosage form includes another dosage portion having another medicament and another release element in another first medicament-release state. In the another first medicament-release state, the another medicament has another first bioavailability to the animal. The another release element is modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal.

Abstract: Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament, and a site and the medicament in a first association. In the first association, the medicament has a first bioavailability. The first association of the site and the medicament is modifiable ex vivo to a second association an exposure to a stimulus, wherein the medicament has a second bioavailability. The final dosage form includes another dosage portion having another medicament, and another site and the another medicament in another first association. In the another first association, the another medicament has another first bioavailability. The another first association is modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability.